Product Description
Mechanisms of Action: OPR Agonist
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Adamis
Company Location: SAN DIEGO CA 92130
Company CEO: David J. Marguglio
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Opioid-Related Disorders
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/21/2023 |
News Article |
DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI |
|
12/21/2023 |
News Article |
DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI |
|
11/28/2023 |
News Article |
DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update |
|
11/28/2023 |
News Article |
DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update |
